Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1957 1
1958 2
1959 6
1960 4
1961 3
1962 1
1963 2
1964 2
1965 4
1966 1
1967 1
1968 1
1969 4
1970 1
1971 3
1972 6
1973 4
1974 4
1975 6
1976 6
1977 4
1978 3
1979 1
1980 1
1981 2
1982 1
1983 1
1984 5
1985 7
1986 8
1987 3
1988 9
1989 5
1990 4
1991 4
1993 1
1994 3
1995 2
1996 1
1997 1
1998 2
1999 4
2017 1
2018 2
2019 1
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

141 results
Results by year
Filters applied: . Clear all
Page 1
The effectiveness of quality control samples in pharmaceutical bioanalysis.
Keller S, Quiroz J, Christopher D, Wickremsinhe E, Geng W, Hawthorne G, James C, Katterle Y, Li W, Liu G, Mayer A, Paton M, Pav J, Potter J, Vergis J, Wang J, Westcott-Baker L, Woolf E, Xue Y. Keller S, et al. Among authors: pav j. Bioanalysis. 2021 Feb;13(3):135-145. doi: 10.4155/bio-2020-0265. Epub 2021 Feb 4. Bioanalysis. 2021. PMID: 33538614
Insulin antibodies.
PAV J, JEZKOVA Z, SKRHA F. PAV J, et al. Lancet. 1963 Aug 3;2(7301):221-2. doi: 10.1016/s0140-6736(63)90117-x. Lancet. 1963. PMID: 13942063 No abstract available.
DEHYDROEPIANDROSTERONE IN OBESE DIABETICS.
SONKA J, GREGORVA I, PAV J, SKRHA F. SONKA J, et al. Among authors: pav j. Lancet. 1964 Jul 4;2(7349):44-5. doi: 10.1016/s0140-6736(64)90041-8. Lancet. 1964. PMID: 14149212 No abstract available.
[Thoughts on insulin therapy].
Páv J. Páv J. Cas Lek Cesk. 1994 Jun 27;133(13):394-6. Cas Lek Cesk. 1994. PMID: 8062330 Review. Czech.
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
Zhou J, Limsakun T, Yin O, Warren V, Zamora C, Atiee G, Kochan J, Pav J, Kobayashi F, Vashi V, Dishy V. Zhou J, et al. Among authors: pav j. J Clin Pharmacol. 2019 Dec;59(12):1669-1677. doi: 10.1002/jcph.1474. Epub 2019 Jun 27. J Clin Pharmacol. 2019. PMID: 31243790 Clinical Trial.
A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor.
Dennie J, Vandell AG, Inoue S, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Uchiyama M, Yamada M, Senaldi G. Dennie J, et al. Among authors: pav j. J Clin Pharmacol. 2018 Dec;58(12):1557-1565. doi: 10.1002/jcph.1151. Epub 2018 May 10. J Clin Pharmacol. 2018. PMID: 29746725 Clinical Trial.
Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.
Vandell AG, Inoue S, Dennie J, Nagasawa Y, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Senaldi G. Vandell AG, et al. Among authors: pav j. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02537-17. doi: 10.1128/AAC.02537-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29439973 Free PMC article. Clinical Trial.
141 results